On July 30, WUXI BIO fell 3.15% in regular trading, trading at HK$38.18/share, with turnover of HK$278 million. The decline came amid broad-based weakness across the Life Sciences Tools and Services sector.

On the news front, the selloff appears linked to sector-wide profit-taking following a strong recent rally, compounded by Nomura's downgrade of WUXI BIO's subsidiary WUXI XDC's target price from HK$87.73 to HK$82.6 on July 29. Nomura cited higher FX losses and elevated management expenses related to the Dong Yao Pharma acquisition, cutting its fiscal year earnings forecast by 22.3%. WUXI XDC itself declined over 4% on the day.

Within the sector, INSILICO fell 2.57%, WUXI APPTEC fell 2.02%, XTALPI fell 1.47%, GENSCRIPT BIO fell 0.92%, and WUXI XDC fell 4.15%. The company is scheduled to report interim results on August 25.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)